Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05700149
Recruiting Observational

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

NCT05700149 · tracked via the Priya Life Science Italy tracker
Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Observational
Started
2024-04-11
Last updated
2026-06-22

Condition(s) studied

Nodal Marginal Zone Lymphoma

Study summary

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Male or female adults 18 years or older 2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000 3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve 4. Availability of the baseline and follow-up annotations Exclusion Criteria: 1\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

Primary outcome measure(s)

  • Define and quantify molecular subsets. — Two years: from the end of samples collection to the end of study analysis

Trial sites (50)

FacilityCityRegionStatus
University of Miami Miami Florida Recruiting
Mayo Clinic Rochester Minnesota Recruiting
Weill Cornell Medical New York New York Recruiting
Ohio Health Riverside Methodist Hospital Columbus Ohio Recruiting
Hospital Italiano de Buenos Aires Buenos Aires Argentina Recruiting
Hematology Center after Prof. Yeolyan Yerevan Armenia Recruiting
Princess Margaret Cancer Centre Toronto Canada Recruiting
University Hospital Centre Zagreb Zagreb Croatia Recruiting
CHU Grenoble Alpes Grenoble France Recruiting
Institut Universitaire du Cancer de Toulouse Toulouse France Recruiting
Tata Memorial Hospital Mumbai India Recruiting
AO SS Antonio e Biagio e C. Arrigo Alessandria AL Recruiting
Istituto Tumori "Giovanni Paolo II" I.R.C.C.S. Bari BA Recruiting
ASST Papa Giovanni XXIII Bergamo BG Recruiting
ASST degli Spedali Civili di Brescia Brescia BS Recruiting
AOU Policlinico Vittorio Emanuele, Presidio Ferrarotto Catania CT Recruiting
Azienda Ospedaliero Universitaria di Ferrara Cona FE Recruiting
Azienda Ospedaliera Universitaria Careggi Florence FI Recruiting
Azienda Ospedaliera Papardo Messina ME Recruiting
IRCCS Ospedale San Raffaele Milan MI Recruiting
IEO Istituto Europeo di Oncologia Milan MI Recruiting
ASST Grande Ospedale Metropolitano Niguarda Milan MI Recruiting
Azienda Sanitaria Locale di Pescara Pescara PE Recruiting
Centro di Riferimento Oncologico Aviano PN Recruiting
Fondazione IRCCS Policlinico San Matteo Pavia PV Recruiting
AUSL IRCCS di Reggio Emilia, Arcispedale S. Maria Nuova Reggio Emilia RE Recruiting
Fondazione PTV - Policlinico Tor Vergata Rome RM Recruiting
Sapienza University - AOU Policlinico Umberto I Rome RM Recruiting
Fondazione Policlinico Univeristario A. Gemelli, IRCCS, Università Cattolica S. Cuore Rome RM Recruiting
ASST dei Sette Laghi - Ospedale di Circolo di Varese Varese VA Recruiting
IRCCS - Azienda Ospedaliero-Universitaria di Bologna Bologna Italy Recruiting
Azienda Ospedaliera Universitaria Federico II Naples Italy Recruiting
AOU Maggiore della Carità Novara Italy Recruiting
Rijnstate Hospital Arnhem Netherlands Recruiting
University Clinical Center, Medical University of Gdansk Gdansk Poland Recruiting
Portuguese Institute of Oncology Lisbon Portugal Recruiting
Chonnam National University Hwasun Hospital Jeollanam-do South Korea Recruiting
Hospital del Mar Barcelona Spain Recruiting
Hospital Clinic I Provincial de Barcelona Barcelona Spain Recruiting
Hospital Universitari de Bellvitge / Institut Català d'Oncologia L'Hospitalet de Llobregat Spain Recruiting

+ 10 more sites — see the full list on the official registry below.

More International Extranodal Lymphoma Study Group (IELSG) trials in Italy

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma Active, not recruiting
Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach Starting soon
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma Active, not recruiting
Molecular and Cellular Characterization of MALT Lymphoma Starting soon
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients Active, not recruiting

Other trials for the same condition

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05700149 on ClinicalTrials.gov ↗ ← All trials in Italy